PALISADE

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results

Retrieved on: 
Thursday, May 9, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Molecule, PALISADE, EAP, American College, FCS, Risk, PIN, Hypertriglyceridemia, Arrowhead, APOC3, RNA, Webcast, Triglyceride, Cardiology, Patient, Cardiovascular disease, Diagnosis, Clinical trial, JAMA Cardiology, Amgen, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024.
  • The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m.
  • Received a $50 million milestone payment from Royalty Pharma plc, which was paid in the third quarter of fiscal 2024, following the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen.
  • Each event will feature presentations by Arrowhead team members and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes.

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

Retrieved on: 
Monday, March 25, 2024
Infectious Diseases, Diabetes, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Arrowhead, Diagnosis, PALISADE, Patient, Hypertriglyceridemia, EAP, Science, Microsoft Access, American College, Clinical trial, RNA interference, FCS, Therapy, Physician, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS) who meet certain program eligibility criteria.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS) who meet certain program eligibility criteria.
  • Arrowhead will also present new final Phase 2 clinical data from the double-blind portion of the SHASTA-2 study of plozasiran in a late-breaking oral presentation at the upcoming American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24), being held in Atlanta on April 6-8, 2024.
  • “Arrowhead is committed to supporting patients living with various lipid disorders and the physicians who treat them.
  • “Our Phase 3 PALISADE study of plozasiran in patients with FCS is nearing completion and we are further supporting the patient community by initiating an expanded access program for patients and physicians interested in receiving treatment with plozasiran outside of a clinical trial.

Hyundai Motor Group Earns Most Combined IIHS TOP SAFETY PICK+ and TOP SAFETY PICK Awards

Retrieved on: 
Wednesday, February 28, 2024
TSP, Kia, Hyundai Motor Group, IIHS, PALISADE, SUV, G90, Quality, Genesis G80, KONA, Safety, Electrification, Hyundai Motor Company, G80, Hyundai, GV70, Telephone

With 10 TSP and six TSP+ awards, the Group, including Hyundai Motor, Kia and Genesis brands, leads the industry with the most combined TSP/TSP+ accolades

Key Points: 
  • With 10 TSP and six TSP+ awards, the Group, including Hyundai Motor, Kia and Genesis brands, leads the industry with the most combined TSP/TSP+ accolades
    Hyundai Motor and Genesis tied for second place overall, with Hyundai Motor securing seven awards (two TSP+ and five TSP), Genesis earning seven awards (three TSP+ and four TSP) and Kia earning two awards (one TSP+ and one TSP)
    SEOUL, South Korea, Feb. 28, 2024 /PRNewswire/ -- Hyundai Motor Group (the Group) is announcing that the Insurance Institute of Highway Safety (IIHS) has honored a total of 16 models from Hyundai Motor Company, Kia Corporation, and Genesis, with the prestigious IIHS 2024 TOP SAFETY PICK (TSP) and TSP+ awards — more than any other automaker in the annual assessment.
  • The Group's exceptional performance in the IIHS 2024 awards is a testament to its unwavering focus on safety.
  • "Hyundai Motor Group is proud to have earned the industry leadership position in the recent IIHS 2024 TSP/TSP+ award results," said Brian Latouf, President and Global Chief Safety and Quality Officer at Hyundai Motor Group.
  • Among the Group's brands, Hyundai Motor and Genesis tied for second place overall, with Hyundai Motor securing seven awards (two TSP+ and five TSP), Genesis earning seven awards (three TSP+ and four TSP) and Kia earning two awards (one TSP+ and one TSP).

Hyundai Motor Group Earns Most Combined IIHS TOP SAFETY PICK+ and TOP SAFETY PICK Awards

Retrieved on: 
Wednesday, February 28, 2024
TSP, Kia, Hyundai Motor Group, IIHS, Multimedia, PALISADE, SUV, G90, Quality, Genesis G80, KONA, Safety, Electrification, Hyundai Motor Company, G80, Hyundai, GV70, Telephone

With 10 TSP and six TSP+ awards, the Group, including Hyundai Motor, Kia and Genesis brands, leads the industry with the most combined TSP/TSP+ accolades

Key Points: 
  • With 10 TSP and six TSP+ awards, the Group, including Hyundai Motor, Kia and Genesis brands, leads the industry with the most combined TSP/TSP+ accolades
    Hyundai Motor and Genesis tied for second place overall, with Hyundai Motor securing seven awards (two TSP+ and five TSP), Genesis earning seven awards (three TSP+ and four TSP) and Kia earning two awards (one TSP+ and one TSP)
    SEOUL, South Korea, Feb. 27, 2024 /PRNewswire/ -- Hyundai Motor Group (the Group) is announcing that the Insurance Institute of Highway Safety (IIHS) has honored a total of 16 models from Hyundai Motor Company, Kia Corporation, and Genesis, with the prestigious IIHS 2024 TOP SAFETY PICK (TSP) and TSP+ awards — more than any other automaker in the annual assessment.
  • "Hyundai Motor Group is proud to have earned the industry leadership position in the recent IIHS 2024 TSP/TSP+ award results," said Brian Latouf, President and Global Chief Safety and Quality Officer at Hyundai Motor Group.
  • Among the Group's brands, Hyundai Motor and Genesis tied for second place overall, with Hyundai Motor securing seven awards (two TSP+ and five TSP), Genesis earning seven awards (three TSP+ and four TSP) and Kia earning two awards (one TSP+ and one TSP).
  • More information about Hyundai Motor Group can be found at:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/hyundai-motor-group-earns-most-...

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, NDA, CNS, Depression, Safety, PMDD, Hot, Food, Menstrual cycle, DSM-IV codes, PALISADE, Alnylam Pharmaceuticals, Initiate, Menopause, Social anxiety disorder, SAD, Clinical trial, Optimism, Patient, Research, Premenstrual dysphoric disorder, FDA, SUDS, Panic, Anxiety, R, Fasedienol, Central nervous system, MDD, Pharmaceutical industry, Sales, Broadcasting

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended September 30, 2023.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended September 30, 2023.
  • To complement the positive top-line results from PALISADE-2, the Company is preparing to launch two similar Phase 3 clinical trials in 2024, PALISADE-3 in the first half of 2024 and PALISADE-4 in the second half of 2024.
  • She joins Vistagen from Alnylam Pharmaceuticals where she served as the Chief Accounting Officer, focused on strategic and financial operations.
  • Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.

Vistagen Announces Pricing of $100 Million Underwritten Offering

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Exercise, Attention, Montgomery Street, Central nervous system, Depression, William Blair & Company, Anxiety, Telephone, Jefferies, SAD, File hosting service, Research, Sale, Suite, Prospectus, Jefferies Group, PALISADE, Social anxiety disorder, Madison Avenue, Security (finance), Therapy, Stifel, L.L.C, Citadel, Incorporated

Each share of common stock or pre-funded warrant will be sold with an accompanying T1 Warrant and T2 Warrant.

Key Points: 
  • Each share of common stock or pre-funded warrant will be sold with an accompanying T1 Warrant and T2 Warrant.
  • The total gross proceeds to Vistagen from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vistagen and excluding any potential future proceeds of up to $50 million from the exercise of the T1 Warrants and up to $100 million from the exercise of the T2 Warrants.
  • All of the shares of common stock, pre-funded warrants, T1 Warrants, and T2 Warrants to be sold in the offering are being sold by Vistagen.
  • The offering is expected to close on October 4, 2023, subject to the satisfaction of customary closing conditions.

Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Neuron, Hot, Optimism, Central nervous system, Depression, Nasal cavity, Anxiety, Aes, New Drug Application, Food and Drug Administration, Calendar, Clinical Global Impression, NDA, Woman, Subjective units of distress scale, SAD, Liebowitz social anxiety scale, Multimedia, Brain, CNS, Trial of the century, Visit, PALISADE, MDD, Patient, LSAS, Menopause, Social anxiety disorder, FDA, Fasedienol, Safety, Pharmaceutical industry, Nursing, Medical imaging, Dietary supplement, SUDS

Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years,” said Shawn Singh, Chief Executive Officer of Vistagen.

Key Points: 
  • Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years,” said Shawn Singh, Chief Executive Officer of Vistagen.
  • Positive Phase 3 PALISADE-2 study of fasedienol yields statistically significant top-line results for the acute treatment of anxiety in adults with SAD.
  • Based on the positive top-line results of the Phase 3 PALISADE-2 study, we are currently preparing for our Phase 3 PALISADE-3 trial, with potential to initiate the trial during the first half of calendar 2024.
  • Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update.

Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results

Retrieved on: 
Monday, August 7, 2023
Genetics, Pharmaceutical, Health, Molecule, GSK, Asthma, Therapy, NASH, Targeted molecular therapy for neuroblastoma, FSHD, CNS, Development, PIN, SOD1, PALISADE, Facioscapulohumeral muscular dystrophy, Patient, Serum, Fatty liver disease, Webcast, RNA interference, ALS, Gene, Disease, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023.
  • The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m.
  • ET to discuss the results.
  • Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Wednesday, June 28, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Columbia University, Hot, Depression, Central nervous system, Liebowitz social anxiety scale, Anxiety, New Drug Application, COVID-19, Fear, Calendar, NDA, Woman, SAD, Fast Track, CNS, New York State Psychiatric Institute, Science, Phase 1, PALISADE, MDD, PH10, Patient, LSAS, Anxiety disorder, Menopause, Principal, PH94B, FDA, Safety, Pharmaceutical industry

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 ended March 31, 2023.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 ended March 31, 2023.
  • Positive results reported from Phase 2A study of PH80 in women diagnosed with vasomotor symptoms (hot flashes) due to menopause.
  • Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update for its fiscal year 2023 ended March 31, 2023.
  • In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Wednesday, June 28, 2023.

Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Retrieved on: 
Tuesday, May 16, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Arrowhead, Trust, PALISADE, Arrowhead Pharmaceuticals, Patient, Dura Pharmaceuticals, Inc. v. Broudo, FCS, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome.
  • The company anticipates that the primary portion of the study will be complete in the second quarter of 2024 with a data readout shortly thereafter and subsequent submissions for regulatory review and approval.
  • Javier San Martin, M.D., chief medical officer at Arrowhead, said: “Completing enrollment of the Phase 3 PALISADE study represents a significant milestone for Arrowhead and brings our potentially important RNAi-based medicines closer to the patients that may benefit from them.
  • I am grateful to the FCS patient community and principal investigators for their trust and participation in the PALISADE study.”